Immunotherapy for sepsis.
In recent years, an improved understanding of the pathogenesis of sepsis, along with an explosion in the biotechnology industry, has led to the development of a variety of agents with potential to interdict the pathogenesis of sepsis at many points. This article reviews the rationale, efficacy and shortcomings of these immunotherapeutic agents as they relate to the management of human septic shock.
Ralston
D R
DR
Division of Pulmonary and Critical Care Medicine, Ohio State University Medical Center, Columbus, USA.
St John
R C
RC
D000818:Animals; D016207:Cytokines / Q000037:antagonists & inhibitors; D004731:Endotoxins / Q000037:antagonists & inhibitors; D016905:Gram-Negative Bacterial Infections / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D018805:Sepsis / Q000628:therapy*
D016207:Cytokines; D004731:Endotoxins